Positive Data Demonstrates Gepotidacin is Non-Inferior to Alternative Treatment in GC
In a trial that compared gepotidacin to ceftriaxone plus azithromycin in patients with urogenital gonorrhea, gepotidacin presented a 92.6% microbiological success rate.